Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bra...
Stay updated with breaking news from Sio Gene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bra...
/PRNewswire/ -- DelveInsight's AAV Vectors in Gene Therapy Market Insights report includes a comprehensive understanding of current treatment practices,...
Sio Gene Therapies Inc. (NASDAQ:SIOX – Get Free Report) was down 3.2% during mid-day trading on Tuesday . The stock traded as low as $0.38 and last traded at $0.38. Approximately 8,586 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 188,696 shares. The stock had previously closed […]
Sio Gene Therapies Inc. (NASDAQ:SIOX – Get Free Report)’s stock price rose 5.1% on Thursday . The company traded as high as $0.39 and last traded at $0.39. Approximately 3,369 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 264,451 shares. The stock had previously closed at $0.37. […]
Sio Gene Therapies (NASDAQ:SIOX – Get Rating) and Organigram (NASDAQ:OGI – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends. Earnings & Valuation This table compares Sio Gene Therapies […]